Deoxynortryptoquivaline: A unique antiprostate cancer agent

Oncol Res. 2023 Sep 15;31(6):845-853. doi: 10.32604/or.2023.030266. eCollection 2023.

Abstract

The androgen receptor (AR) is a critical target in all the clinical stages of prostate cancer. To identify a new AR inhibitor, we constructed a new screening system using the androgen-dependent growth of prostate cancer cell lines as a screening indicator. We screened 50,000 culture broths of microorganisms using this screening system and found that the fermentation broth produced by a fungus inhibited androgen-dependent growth of human prostate cancer LNCaP cells without cytotoxicity. Purification of this culture medium was performed, and this resulted in deoxynortryptoquivaline (DNT) being identified as a novel inhibitor of AR function. DNT showed potent inhibition of androgen-dependent growth of human prostate cancer LNCaP cells. The AR competitor assay was performed, and DNT did not act as an AR antagonist. However, DNT inhibited AR-dependent transcriptional activity and AR nuclear translocation, it suggested that the suppression of AR function leads to inhibition activity against androgen-dependent growth.

Keywords: Androgen dependency; Androgen receptor; Anticancer antibiotics; Prostate cancer.

MeSH terms

  • Androgens*
  • Cell Line
  • Humans
  • Male
  • Prostatic Neoplasms* / drug therapy

Substances

  • Androgens